Related Experiment Videos
Delayed neurotoxicity in primary central nervous system lymphoma
Antonio M P Omuro1, Leah S Ben-Porat, Katherine S Panageas
1Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Archives of Neurology
|October 12, 2005
Summary
Radiotherapy for primary central nervous system lymphoma (PCNSL) can cause delayed neurotoxicity, a progressive dementia. Radiotherapy was the primary predictor of this adverse effect, suggesting a need for further research into prevention and treatment strategies.
Area of Science:
- Neuro-oncology
- Radiation oncology
- Neurology
Background:
- Chemotherapy and radiotherapy improve survival for primary central nervous system lymphoma (PCNSL).
- However, some patients experience delayed neurotoxicity, a poorly defined treatment-related complication with unknown mechanisms.
Purpose of the Study:
- To characterize the clinical presentation, temporal course, and potential pathophysiologic mechanisms of neurotoxicity following PCNSL treatment.
- To generate hypotheses for future research on preventing and treating this complication.
Main Methods:
- Retrospective review of 185 patients treated for PCNSL.
- Analysis included 43 patients who developed neurotoxicity.
- Evaluated risk factors, clinical course, and neuropsychological, neuroimaging, and histologic findings.
Main Results:
- The 5-year cumulative incidence of neurotoxicity was 24%, increasing over time.
- Neurotoxicity manifested as subcortical dementia with cognitive, behavioral, and motor deficits.
- Diffuse white matter disease and atrophy were observed on imaging; autopsy revealed white matter damage and microvascular changes.
- Radiotherapy was the only significant predictor of neurotoxicity in multivariate analysis (P<.001).
Conclusions:
- Findings suggest radiation-induced damage to frontal-subcortical circuits is the primary mechanism.
- Potential causes include microvascular alterations, oligodendrocyte progenitor loss, or oxidative stress.
- Further studies are needed to address prevention and treatment of PCNSL-related neurotoxicity.